ALK-Abelló A/S (AKBLF)
AKBLF Stock Price Chart
Explore ALK-Abelló A/S interactive price chart. Choose custom timeframes to analyze AKBLF price movements and trends.
AKBLF Company Profile
Discover essential business fundamentals and corporate details for ALK-Abelló A/S (AKBLF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Nov 2009
Employees
2.74K
Website
https://www.alk.netCEO
Peter Halling
Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
AKBLF Financial Timeline
Browse a chronological timeline of ALK-Abelló A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 13 Nov 2025
Revenue estimate is $1.47B.
Earnings released on 21 Aug 2025
Revenue for the quarter reached $240.55M , missing expectations by -83.44%.
Earnings released on 6 May 2025
EPS came in at $0.24 surpassing the estimated $0.20 by +20.40%, while revenue for the quarter reached $224.01M , missing expectations by -85.11%.
Earnings released on 19 Feb 2025
EPS came in at $0.78 falling short of the estimated $1.00 by -22.00%, while revenue for the quarter reached $207.46M , missing expectations by -0.42%.
Earnings released on 14 Nov 2024
EPS came in at $1.00 surpassing the estimated $0.12 by +744.59%, while revenue for the quarter reached $193.19M , missing expectations by -87.40%.
Earnings released on 22 Aug 2024
EPS came in at $0.90 surpassing the estimated $0.60 by +50.00%, while revenue for the quarter reached $197.84M , beating expectations by +0.89%.
Earnings released on 2 May 2024
EPS came in at $1.10 surpassing the estimated $1.00 by +10.00%, while revenue for the quarter reached $194.00M , beating expectations by +5.16%.
Earnings released on 8 Feb 2024
EPS came in at $0.70 surpassing the estimated $0.11 by +525.00%, while revenue for the quarter reached $198.48M , missing expectations by -0.74%.
Earnings released on 15 Nov 2023
EPS came in at $0.50 surpassing the estimated $0.05 by +864.32%, while revenue for the quarter reached $156.62M , missing expectations by -0.45%.
Earnings released on 24 Aug 2023
EPS came in at $0.30 surpassing the estimated $0.04 by +689.68%, while revenue for the quarter reached $165.81M , beating expectations by +2.25%.
Earnings released on 9 May 2023
EPS came in at $0.70 surpassing the estimated $0.07 by +915.38%, while revenue for the quarter reached $179.90M , beating expectations by +0.94%.
Earnings released on 3 Feb 2023
EPS came in at $0.35 surpassing the estimated $0.04 by +700.37%, while revenue for the quarter reached $180.40M , beating expectations by +3.94%.
Stock split effective on 25 Nov 2022
Shares were split 20 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at $0.23 surpassing the estimated $0.01 by +1.84K%, while revenue for the quarter reached $139.19M , beating expectations by +2.43%.
Earnings released on 11 Aug 2022
EPS came in at $0.19 surpassing the estimated -$0.00 by +4.68K%, while revenue for the quarter reached $146.73M , beating expectations by +8.10%.
Earnings released on 12 May 2022
EPS came in at $0.74 surpassing the estimated $0.07 by +895.43%, while revenue for the quarter reached $171.78M , beating expectations by +2.20%.
Stock split effective on 8 Apr 2022
Shares were split 20 : 1 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 29 Mar 2022
Shares were split 20 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Feb 2022
EPS came in at $0.35 surpassing the estimated $0.03 by +1.11K%, while revenue for the quarter reached $167.50M , beating expectations by +2.35%.
Earnings released on 11 Nov 2021
EPS came in at $0.17 falling short of the estimated $0.19 by -10.53%, while revenue for the quarter reached $144.79M , missing expectations by -84.06%.
Earnings released on 11 Aug 2021
EPS came in at -$0.09 falling short of the estimated -$0.02 by -280.07%, while revenue for the quarter reached $138.37M .
Earnings released on 5 May 2021
EPS came in at $0.57 surpassing the estimated $0.47 by +21.28%, while revenue for the quarter reached $161.30M .
Earnings released on 10 Feb 2021
EPS came in at -$0.14 falling short of the estimated $0.18 by -177.78%, while revenue for the quarter reached $162.72M .
Earnings released on 11 Nov 2020
EPS came in at -$0.09 surpassing the estimated -$0.16 by +43.75%, while revenue for the quarter reached $121.66M .
AKBLF Stock Performance
Access detailed AKBLF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.